Treatment of Membranoproliferative Glomerulonephritis in Adolescents Aged 12–17 with C3 Glomerulopathy or Primary IC-MPGN

Clinical Scenario

This protocol addresses membranoproliferative glomerulonephritis (MPGN) specifically in adolescents between the ages of 12 and 17 years who have C3 glomerulopathy (C3G) or primary immune complex MPGN (IC-MPGN). This age-defined population requires a structured, evidence-based approach tailored to its distinct clinical context.

Treatment Approach

The approach centres on general supportive care targeting the key manifestations of glomerular disease — including edema, proteinuria, and hypertension — through a combination of lifestyle modifications and pharmacological measures that include RAAS blockade and antiproteinuric agents, with additional interventions as indicated.

The complete agent selection, sequencing, and full clinical algorithm are available in the structured protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.ekir.2025.10.020

In 2025, pegcetacoplan was also approved by the US Food and Drug Administration for the treatment of adult and pediatric patients aged $ 12 years with C3G or primary IC-MPGN to reduce proteinuria.
Adolescents (12–17 yrs old), n (%)
General supportive care for all patients with glomerular diseases who have edema, proteinuria and/or hypertension
RAASi (e.g. ACEi or ARBs) and potentially other antiproteinuric agents
Alternative anti-hypertensives (e.g. CCBs)

View source ↗